Asthma, Asthma in Children
Conditions
Keywords
microbiosme, Asthma in infant
Brief summary
Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment. Exploring and understanding these data is to improve patient care and discover new therapeutic targets. The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.
Interventions
OTHERBlood sample
An additionnal volume of blood will be collected at inclusion and at each follow-up visit
OTHERExpectoration
Expectoration will be collected at inclusion and at each follow-up visit
OTHERNasopharyngeal swab
A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 24 Months
Healthy volunteers
No
Inclusion criteria
* Infants less than 24 months old * Follow-up by a pneumo-pediatrician for severe asthma in infants * Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009) * Parent informed of the research and having signed consent
Exclusion criteria
* Prematurity \<32 WA * Congenital heart disease with significant left to right shunt * Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans) * Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization) * Refusal of bronchial fibroscopy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| description of microbiomes from bronchoalveolar fluids | Inclusion | analysis of bronchoalveolar fluids - NGS sequencing |
| description of microbiomes from nasopharyngeal samples | Inclusion | analysis of nasopharyngeal samples- NGS sequencing |
| description of microbiomes from sputum samples | Inclusion | analysis of sputum samples- NGS sequencing |
| Description of microbiomes from sputum samples | at 12 months | analysis of sputum samples- NGS sequencing |
Countries
France
Contacts
CONTACTDavid Mallet
PRINCIPAL_INVESTIGATORPETAT Hortense
University Hospital, Rouen
Outcome results
None listed